Clinical trial

Impact of Thoracic Duct Ligation on Postoperative Weight Reduction in Obese Patients Receiving Minimally Invasive Lung Surgery: A Clinical Investigation

Opening soon · Not applicable · 0 countries · Registry ID NCT06995599

Opening soonNot applicableInterventional

What this study is about

This clinical trial aims to investigate whether thoracic duct ligation (TDL) can improve obesity and lipid metabolism. The primary questions it seeks to answer are: Whether thoracic duct ligation can improve BMI and lipid metabolism in obese patients. The safety and feasibility of thoracic duct ligation as a treatment for obesity.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Days to 75 Days

SexAll

Healthy volunteersNot accepted

ConditionObese Patients

Full registry criteria

Inclusion Criteria: 1. Age \& Gender: Individuals aged 18-75 years, regardless of gender. 2. Clinical Profile:Diagnosed with early-stage lung cancer (stage IA1-IB) and obesity (BMI ≥28 kg/m²). 3. Scheduled to undergo video-assisted thoracoscopic surgery (VATS) for right-sided lung cancer resection at our institution between October 2024 and October 2026. 4. Surgical Eligibility: Approved for surgery following multidisciplinary team (MDT) assessment. 5. Treatment Plan: No requirement for adjuvant therapy post-lung resection. 6. Preoperative Evaluation:Completed standard preoperative workup, including: 7. Chest CT、Brain CT/MRI、Abdominal ultrasound OR PET-CT to rule out distant metastasis. 8. Informed Consent: Willing and able to comply with study requirements, with written informed consent provided. Exclusion Criteria: 1. Concurrent Thoracic Infections: Patients with active intrathoracic infectious diseases (e.g., inflammatory conditions, tuberculosis). 2. Refusal of Novel Technique: Patients unwilling to undergo intraoperative thoracic duct ligation. 3. Clinically Unstable Comorbidities: Severe, unstable cardiovascular, renal, or respiratory disorders. 4. Prior Bariatric Surgery: History of weight-loss surgery (e.g., gastric bypass, sleeve gastrectomy). 5. Recent Trial Participation: Enrollment in other clinical trials within 30 days prior to screening. 6. Investigator Discretion: Other conditions deemed by the investigator to contraindicate participation.

Treatments and study arms

Thoracic Duct Ligation (TDL)

Procedure

Following the minimally invasive right-sided lung cancer resection, during mediastinal lymph node dissection, the posterior aspect of the azygos vein is identified. The mediastinal pleura is then longitudinally incised along the medial border of the azygos vein and posterior to the esophagus. Between the azygos vein and aorta, the thoracic duct is meticulously localized as a milky-white translucent structure measuring 2-3 mm in diameter. A 5-mm segment of the duct is carefully mobilized and double-clamped with vascular clips under direct thoracoscopic visualization. The surgical field is thoroughly inspected to confirm the absence of chylous leakage, and the procedure is concluded after standard closure and confirmation of hemostasis.

Primary outcomes

Height and weight (for BMI calculation)Height and weight (for BMI calculation) : Measured at baseline, postoperative 1/4/ 7/10/13/19/25/37months.;Lipid profile (LDL/HDL): Baseline, postoperative 1/5day, 1/4/ 7/10/13/19/25/37months.Participants will be followed for up to 36 months .

Height and weight (for BMI calculation)

Study locations

0 locations were listed when this page was built. The first 40 are shown.

No public site location was included in this record. Check the original registry for updates.